Genetic Epidemiological Evidence Indicates the Role of Lipid Control in Omega‑3‑Mediated Cardiovascular Protection

Jinhan **Yu**[1,#]; Chengjia **Li**[1,#]; Zipeng, **Liu**[2]; Yidan **Chen**[1]; Yao **Lei**[3]; Dingyang **Li**[1]; Wen **Ma**[4]; Yao **Wang**[5]; Yi **Yang**[6]; Renzhi **Wang**[1]; Yong-Fei **Wang**[1,*]

Author affiliations

1. School of Medicine, Warshel Institute for Computational Biology, The Second Affiliated Hospital, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
2. Clinical Data Center, Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China
3. Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China
4. School Board of Decision Sciences, The Hang Seng University of Hong Kong, Hong Kong, China
5. Department of Obstetrics and Gynaecology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
6. Department of Nephrology, Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, Zhejiang, China

#These authors contributed equally.

*Correspondence to: Yong-Fei Wang (yfwang@cuhk.edu.cn)

Abstract

Background: The association between omega-3 fatty acids and cardiovascular disease has been examined in populations with established disease. However, the definitive role of omega-3 fatty acids in cardiovascular risk remains inconclusive, and evidence from general populations is still limited. This study aims to examine the causal relationship between omega-3 and cardiovascular disease using large-scale genetic data.

Methods: We employed five well-established mendelian randomization (MR) methods to investigate the causal association between omega-3 and cardiovascular events. Two large independent omega-3 GWAS (>110,000 participants each) from general populations were analyzed across 14 cardiovascular and metabolic phenotypes (>50,000 participants each). To understand the direct effect of omega-3 on coronary artery disease (CAD), multivariable MR (MVMR) model and mediation analysis were conducted. Summary-data-based MR (SMR) was applied to identify circulating proteins associated with omega-3 levels.

Results: Genetically elevated omega-3 levels were found associated with increased cardiovascular risk across all MR methods, particularly for CAD (P_{median} = 2.65E-04), myocardial infarction (P_{median} = 1.03E-07) and heart failure (P_{median} = 4.84E-03). Higher genetically predicted omega-3 were linked to elevated LDL-C (P_{median} = 2.50E-33) and its key component apolipoprotein B (P_{median} = 5.60E-08), while reducing triglyceride levels (P_{median} = 4.16E-03). Notably, after adjusting for the genetic effect of LDL-C, omega-3 demonstrated a protective effect on CAD ($\beta_{combined}$ = -0.025, $P_{combined}$ = 0.022), which was strengthened by adjusting for both LDL-C and triglycerides. Mediation analysis suggests that omega-3 is likely to increase CAD risk through elevating LDL-C (P_{median} = 2.40E-12), highlighting the need for effective LDL-C management to maximize the cardiovascular benefits of omega-3. Circulating proteins, such as ANGPTL3 (P_{smr} = 1.22E-27) and PCSK9 (P_{smr} = 1.15E-21), were also found positively associated with omega-3 levels. A reanalysis of clinical trial data confirmed that the cardiovascular

benefits of omega-3 were closely related to the intensity of LDL-C lowering therapy.

Conclusions: Our results suggest that the cardiovascular benefits of omega-3 fatty acids may depend on effective lipid management, particularly LDL-C control. Combining omega-3 supplementation with advanced lipid-lowering therapy may be critical for maximizing their protective impact on cardiovascular health.

Keywords: Omega-3 fatty acid, lipid control, cardiovascular dieases, LDL-C, Mendelian randomization

Introduction

Omega-3 fatty acids, a type of polyunsaturated fatty acids (PUFAs), have long been investigated for their potential protective effects on cardiovascular health[1,2]. However, evidence from two large-scale randomized clinical trials (RCTs) remains inconclusive. The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT, n = 8,179; NCT01492361) reported that high-dose icosapent ethyl (a purified and stable EPA ethyl ester, 4g/d) significantly reduced major cardiovascular events by 25% in patients with hypertriglyceridemia[3]. But concerns have been raised regarding the use of mineral oil as placebo. In contrast, the Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH, n = 13,078; NCT02104817) trial found no significant cardiovascular benefit with omega-3 CA (a carboxylic acid formulation of EPA and DHA, 4g/d) compared to corn oil over a median follow-up of 42.0 months[4].

Previous studies were primarily conducted in populations with cardiovascular-related conditions[3,4], and the conflicting results demonstrated the challenges in investigating a clear causal relationship between omega-3 fatty acids and cardiovascular outcomes. These inconsistencies may result from placebo selection, drug use, dosing regimens, study populations, and the difficulty of controlling numerous confounding factors. Mendelian randomization (MR) offers a way to address these limitations by using genetic variants as instrumental variables (IVs) for exposures. This method reduces bias from potential confounders, as genetic variants are randomly allocated at conception and remain independent of most environmental and behavioral factors[5,6]. In addition, recent large-scale genome-wide associations studies (GWAS) of circulating metabolic traits[7-11] and cardiovascular diseases[12-18] provide valuable resources, offering a strong foundation for MR studies to explore the causal relationships between omega-3 levels and cardiovascular outcomes.

To date, at least 16 MR methods have been developed, with key differences in the selection of IVs, modeling, and techniques to control potential pleiotropy[19,20]. Among these, the inverse variance weighed (IVW) fixed-effects model remains the most widely used method. However, due to its higher susceptibility to type I error, MR-Egger[21], Weighted-mode[22], and MR-APSS[23] models were also incorporated in this study. These new methods have shown robust control of type I errors and improved accuracy in estimating causal effects under diverse conditions in both simulated and real-world data[20,24].

To ensure a robust causal inference, we integrated data from two large independent GWAS of circulating omega-3[9,25] with genetic data on 14 cardiovascular and metabolic phenotypes, each involving more than 50,000 participants (**Figure 1**). This study aims to systematically examine the causal relationships between omega-3 levels and cardiovascular risk using large-scale genetic data.

Methods

Study design and data sources

The full GWAS summary statistics used in this analysis were primarily obtained from the GWAS Catalog[26], with detailed information provided in **Table S1**. These GWAS were predominantly conducted in European populations. To ensure adequate statistical power, we included only studies with at least 50,000 participants. Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research.

We collected two independent GWAS datasets for circulating omega-3 measurement as the exposure (**Figure 1**). The primary exposure dataset was derived from a multi-cohort meta-analysis, involving 136,016 participants[9], while the secondary exposure dataset was sourced from the UK Biobank, including 115,006 individuals[25]. Notably, there was no sample overlap between these two datasets, strengthening the validity of our findings. DHA measurements from the UK Biobank[25] were also included as the exposure. Summary statistics for other metabolic traits, including total cholesterol, low-

density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride, apolipoprotein B (ApoB), apolipoprotein A (ApoA)[7-10], were also mainly sourced from the two studies. Most participants in the multi-cohort study were fasted before blood collection[9], whereas the UK Biobank participants were generally non-fasted, with precise fasting intervals recorded and adjusted for in the analyses[25]. Both studies controlled for age, sex, fasting status, sample type, and relevant covariates, such as body mass index (BMI) and smoking status. These analytical strategies have been well validated and demonstrated in their publications[9,25].

We also collected GWAS summary statistics for a broad range of cardiovascular outcomes, including coronary artery disease (CAD)[12,14], myocardial infarction (n = 639,221)[13], heart failure (n = 977,323)[15], atrial fibrillation (n = 583,168)[16], stroke (n = 446.696)[17] , and its ischemic subtype (n = 440328)[17]. Two CAD GWAS datasets were analyzed: (i) a recent European meta-analysis with 181,522 cases and 1,165,690 controls[12], and (ii) the UK Biobank (34,541 cases and 261,984 controls)[14]. We also incorporated data for hypertension (n = 56,637)[11] and type 2 diabetes (T2D, n = 659,316)[18] due to their strong connection to cardiovascular disease, while type 1 diabetes (T1D, n = 173,981)[27], a type of autoimmune diseases, was included for comparison. Age, sex, principal components and relevant study-specific covariates were adjusted and validated in their publications.

We used the STROBE reporting guideline[28-30] to draft this manuscript, and the STROBE reporting checklist when editing, included in **Table S7.**

Instrumental variable selection

Common SNPs (minor-allele frequency > 1 %) associated with omega-3 levels at genome-wide significance level (P < 5.00E-08) were selected. Correlated variants were then removed by linkage disequilibrium (LD) clumping (1-Mb window, r^2 < 0.05) based on the 1,000 Genomes European panel. To mitigate pleiotropic SNPs, we further applied Steiger filtering[31] discarding SNPs that explained more variance in the outcome than in the exposure, maintaining the correct causal direction.

Mendelian randomization analyses

To ensure the robustness of our MR results, we employed four well-established MR algorithms, as evaluated in previous studies[19,20]. These included: (i) IVW Fixed-effects[32], (ii) MR-Egger[21], (iii) Weighted Mode[22], and (iv) APSS[33]. In addition, given that the *FADS* variant accounts for a large proportion of variance in omega-3 levels[34], we performed a single-variant Wald Ratio analysis[35] using rs174564 or a proxy SNP in strong LD ($r^2 > 0.9$). A causal association was accepted when at least three of the five tests yielded statistically significant results with consistent directional effects. The significance threshold for *P* values was adjusted using Bonferroni correction.

To ensure comparability between datasets, we standardized the SNP-effect estimates and their standard errors (SE). Each raw effect (β) was divided by its SE to create a Z-score, which we then rescaled by $\sqrt{n}$ (n = sample size) to produce a unit-free effect ($Z/\sqrt{n}$). The corresponding SE was set to $1/\sqrt{n}$. This transformation eliminates differences in measurement units and variance across studies, ensuring that subsequent instrumental-variable analyses are conducted on a consistent scale.

SNP-exposure and SNP-outcome datasets were harmonized using the TwoSampleMR package (version 0.5.11)[36]. IVW Fixed-effects model, MR-Egger, Weighted Mode, and Wald Ratio analyses were also conducted using this package. APSS was implemented with the MRAPSS package (0.0.0.9), which restricted the analysis to SNPs in the HapMap 3 reference panel. The background parameters were estimated by LD score regression[37], with the LD score calculated from the 1,000 Genomes European panel.

Multivariable mendelian randomization analysis

Multivariable mendelian randomization (MVMR) analysis was performed using the TwoSampleMR package (version 0.5.11) to estimate the direct association of omega-3 levels with CAD. The models were sequentially adjusted for LDL-C, triglycerides and then for both together. IVs for omega-3 fatty acids, LDL-C, and triglycerides were selected independently based on predefined criteria. LD clumping (1-Mb window, $r^2 < 0.05$) was subsequently

conducted to ensure instrument independence. Effect alleles were harmonized across both exposures and the outcome datasets.

Mediation analysis

Mediation analysis[38] was applied to partition the effect of genetically predicted omega-3 on the CAD into a direct and an indirect effect mediated through LDL-C. The total effect was estimated using the four well established MR algorithms, respectively. Indirect effects were assessed using a two-step MR framework (**Figure 4b**): (1) estimating the effect of omega-3 on LDL-C (β_{step1}), and (2) estimating the effect of LDL-C on CAD (β_{step2}). The indirect effect was then calculated using the product method as $\beta_{step1} \times \beta_{step2}$[39,40].

To estimate the SE of the indirect effect, we applied two approaches: (1) the Delta method approximates the variance using the delta rule, yielding a closed-form solution ($SE_{indirect} = \sqrt{(\beta_{step1}^2 * SE_{step2}^2 + \beta_{step2}^2 * SE_{step1}^2)}$[41] but potentially underestimating variability when coefficient distributions are skewed; (2) the Monte Carlo (MC) method generated empirical confidence intervals by repeatedly sampling[42], offering greater robustness at the expense of higher computational cost. Both methods were implemented to ensure robustness of our inference.

Protein quantitative trait loci data analysis

Summary-data-based mendelian randomization (SMR)[43,44] was applied to identify plasma proteins associated with omega-3 levels. To differentiate true associations from those arising due to LD, we incorporated the heterogeneity in dependent instruments (HEIDI) test[44]. These analyses were conducted using the SMR portal[43], leveraging protein quantitative trait loci (pQTL) summary statistics obtained from the Fenland study (n = 10,708)[45]. Associations were considered statistically significant if they met the following criteria: (i) the lead SNP in omega-3 GWAS passed the genome-wide significant threshold (P < 5.00E-08); (ii) the SMR test passed a Bonferroni-corrected threshold (P_{SMR} < 2.59E-05; 0.05/1,927); and (iii) there was no evidence of horizontal pleiotropy due to LD (P_{HEIDI} > 0.01). Proteins were considered associated with omega-3 if significant associations were

226 confirmed in both omega-3 GWAS. Gene set enrichment analysis was
227 conducted using ToppGene Suite[46]. Regional plots were generated by R
228 package locuscomparer (Version 1.0.0)[47].

Results

Genetically elevated omega-3 levels increase the risk of cardiovascular outcomes

Summary statistics from a GWAS of omega-3 measure in 136,016
participants[9] were used as the primary exposure dataset. The causal effects
on seven cardiovascular-related outcomes were examined using five MR
estimates (**Methods**). A causal association was considered robust when at
least three methods showed consistent effect directions and met the
Bonferroni-corrected significance threshold ($P < 0.00625$; 0.05/8).

Our analysis showed that genetically elevated omega-3 levels have a
significant causal effect on the risk of CAD (P_{median} = 2.65E-04), with
consistent effect directions across all MR estimates (**Figure 2a**). These
results were consistent when using the CAD GWAS exclusively from the UK
Biobank (P_{median} = 2.87E-07). Similar causal relationships were observed for
myocardial infarction (P_{median} = 1.03E-07) and heart failure (P_{median} = 4.84E-03).
We also observed modest effects of omega-3 on the risk of atrial fibrillation
(P_{median} =0.041), stroke (P_{median} = 0.038) and its ischemic subtype (P_{median} =
0.035). Although these associations did not meet the Bonferroni-corrected
significance threshold, the directions of causal effects were consistent across
all five MR estimates. In comparison, no causal effects were observed for T2D
(P_{median} = 0.139) and T1D (P_{median} = 0.297).

We repeated the analysis using the secondary omega-3 GWAS from UK
Biobank. The results confirmed the causal association of increased omega-3
levels with higher risks of CAD (P_{median} = 2.94E-03 and 5.45E-05 for
respective datasets), myocardial infarction (P_{median} = 1.27E-03) and heart
failure (P_{median} = 4.60E-03). All five MR estimates pointed in the same direction
(**Figure S1a**). The positive association with atrial fibrillation (P_{median} = 0.065),

stroke (P_{median} = 0.140), and ischemic stroke (P_{median} = 0.044) still exists,
whereas no associations were detected for T2D (P_{median} = 0.126) and T1D
(P_{median} = 0.727). We also repeated the analyses using a GWAS of DHA as
the exposure. The results were highly consistent, demonstrating a significant
causal effect of elevated DHA levels on the risks of cardiovascular outcomes
(**Figure S2**).

We next conducted sensitivity analyses by excluding genetic variants in the
FADS gene cluster (hg19; chr11:61,067,097–62,134,826), as the fatty acid
desaturases encoded in this region directly involve omega-3 metabolism[48].
The causal association with CAD (P_{median} = 9.47E-08 and 8.39E-07 for
respective datasets), myocardial infarction (P_{median} = 5.70E-06) and heart
failure (P_{median} = 0.016) remained significant and directionally consistent
(**Figure 3a**). These findings were consistent in the secondary omega-3 GWAS
(**Figure 3b**).

Reverse MR analyses were also conducted using genetic variants associated
with cardiovascular outcomes as IVs. No evidence of reverse causal
associations was observed (**Figure S3**), suggesting a unidirectional
relationship in which omega-3 levels influence cardiovascular outcomes.
Taken together, our results suggest that elevated omega-3 levels may
increase cardiovascular risk, particularly CAD, myocardial infarction, and
heart failure.

Omega-3 elevates LDL-C while lowering triglycerides

We further examined the causal influence of omega-3 fatty acids on related
metabolic traits. Similarly, a causal association was considered robust if at
least three methods showed consistent directions and met the Bonferroni-
corrected significance threshold (P < 0.0071; 0.05/7).

Our analyses indicated that genetically elevated omega-3 levels significantly
increased total cholesterol (P_{median} = 7.40E-33), especially LDL-C (P_{median} =
2.50E-33). These results were highly consistent across the five MR methods
(**Figure 2b**). In contrast, no significant effect was observed for HDL-C (P_{median}
= 0.079) and hypertension (P_{median} = 0.215). This pattern extended to key

apolipoproteins, with a significant effect found on ApoB (P_{median} = 5.60E-08), the key component of LDL particles, while no association was found for ApoA (P_{median} = 0.276), the key component of HDL particles. The causal effects on LDL-C and ApoB were also replicated using another independent omega-3 GWAS from UK Biobank (**Figure S1b**). Sensitivity analyses were also performed by excluding genetic variants within the *FADS* gene cluster. Strong positive causal associations of omega-3 with LDL-C and ApoB levels were still observed (**Figure S4**).

To address potential influence of horizontal pleiotropy between omega-3 and LDL-C mentioned in previous studies[49], we adopted more stringent criteria for selecting IVs. Only genetic variants associated with omega-3 levels ($P <$ 5.00E-08) but not associated with LDL-C levels ($P >$ 0.05), were included in the MR analyses. Despite the reduced statistical power, a positive causal association between omega-3 and LDL-C remained evident ($P <$ 0.019; **Figure S5**).

In addition to LDL-C, our analyses demonstrated that genetically elevated omega-3 levels significantly lowered triglycerides (P_{median} = 4.16E-03). This result was also confirmed by another triglyceride GWAS data[8] (P_{median} = 6.80E-04; **Figure 2b**). A consistent direction of effect on triglyceride lowering was also observed when utilizing the omega-3 GWAS derived from UK Biobank as the exposure (**Figure S1b**). These findings align with the American Heart Association (AHA)'s recommendation of omega-3 for reducing triglycerides[50]

However, exclusion of genetic variants within the *FADS* gene cluster reversed this association in a positive direction. This result was further validated using the secondary omega-3 GWAS data (**Figure S4**), highlighting the complex role of omega-3 in triglyceride reduction. Specifically, the triglyceride-lowering effect could be primarily mediated through fatty acid desaturase activity, while omega-3-associated variants outside the *FADS* cluster were linked to increased triglyceride levels. These findings suggest that the effectiveness of omega-3 supplementation in reducing triglycerides may depend on an individual's fatty acid desaturase activity.

To validate these findings, we revisited data from previous clinical trials. To minimize the influence of cholesterol-lowering drugs, we first analyzed data from the Comparing EPA to DHA trial (ComparED; NCT01810003)[51], which assessed changes in blood lipids following EPA or DHA intake among adults without a history of cardiovascular disease[51]. Compared to corn oil, both EPA and DHA significantly increased LDL-C levels while reducing triglycerides. This effect was markedly stronger with DHA, demonstrating a mean LDL-C increase of 0.16 mmol/L ($P < 0.0001$) and a mean triglyceride reduction of 0.25 mmol/L ($P < 0.0001$) over a 10-week follow-up[51].

Next, we revisited data from the STRENGTH trial[4]. Although all participants were on statin therapy, those in the omega-3 CA group still showed a significant increase in LDL-C compared with the corn oil group (geometric mean ratio = 1.03; $P < 0.001$) and a substantial reduction in triglyceride levels (geometric mean ratio = 0.82; $P < 0.001$)[4].

We also investigated data from the REDUCE-IT trial[3]. Due to the use of mineral oil as the control, between-group comparisons were not considered. As all participants were receiving statin therapy, LDL-C were expected to be reduced[52]. However, within the icosapent ethyl group, LDL-C levels increased by 3.1 % from the baseline ($P < 0.001$). Triglycerides decreased by 18.3 % ($P < 0.001$) following 12 months of treatment. Collectively, findings from previous clinical trials supported our MR results that omega-3 fatty acids can elevate LDL-C levels while lowering triglycerides.

The protective effect of omega-3 on CAD depends on lipid control

To evaluate the impact of LDL-C, we estimated the effect of omega-3 on cardiovascular outcome by controlling LDL-C-associated variants using MVMR algorithm (**Methods**). To maximize statistical power, CAD was selected as the outcome due to its largest sample size and the availability of additional CAD dataset for replication. Our results showed that, after adjusting for LDL-C's genetic contribution, the effect of omega-3 on CAD became protective. The association remained consistent when replicated using the

secondary omega-3 GWAS or an alternative CAD GWAS, yielding a
combined effect estimate of approximately -0.025 ($P_{combined}$ = 0.0225) (**Figure**
4a and **Table S2**). In contrast, adjusting for the genetic variants associated
with triglycerides didn't change the direction of the associations (**Figure 4a**
and **Table S3**). However, we found that adjusting for the genetic effects of
both LDL-C and triglycerides further strengthened omega-3's protective
association with CAD ($\beta_{combined}$ = -0.066, $P_{combined}$ = 1.28E-11; **Figure 4a** and
Table S4). These findings highlight the critical role of lipid control, particularly
LDL-C, in optimizing the cardioprotective effects of omega-3.

To further evaluate the role of LDL-C in mediating the effect of omega-3 fatty
acids on CAD risk, we utilized mediation analysis to decompose the total
effect into direct and indirect components (**Methods**). The indirect effect on
CAD through LDL-C was significant (β_{median} = 0.031; P_{median} = 2.40E-12;
Figure 4b), explaining approximately 38.0–81.9% of the total effect across
four MR estimates (**Figure 4b** and **Table S5**). These results remained robust
when replicated using an alternative CAD GWAS (**Figure S6** and **Table S5**).
These findings suggest LDL-C as a major mediator of the association
between elevated omega-3 and CAD risk and highlight the potential
importance of targeting LDL-C reduction in this pathway.

To validate the significance of LDL-C management in optimizing omega-3
benefits, we reanalyzed data from the STRENGTH and REDUCE-IT trials,
both of which evaluated the effect of high-dose omega-3 on cardiovascular
events[3,4]. Subgroup analyses support our findings (**Figure 4c**). In STRENGTH,
compared to corn oil, omega-3 CA appeared more effective in participants
receiving high-intensity statin therapy (Hazard Ratio [HR] = 0.94) than in other
participants (HR = 1.04), though this difference did not reach statistical
significance (P = 0.28). Notably, in participants receiving combined statin and
ezetimibe therapy, a regimen that achieves greater LDL-C reduction, omega-3
CA significantly lowered cardiovascular risk compared to corn oil (HR = 0.54,
95% Confidence Interval [CI]: 0.34-0.86; P = 0.0094)[53].

A similar trend was observed in the REDUCE-IT trial, where icosapent ethyl
conferred a significant cardiovascular benefit over mineral oil among

participants receiving high-intensity statin therapy (HR = 0.69, 95% CI: 0.58–

0.82; P = 2.60E-05). In contrast, no benefit was seen in the low-intensity statin

group (HR = 1.12, 95% CI: 0.74–1.69; P = 0.59). The difference between the

two groups was significant (Cochran's Q, P = 0.034), indicating that patients

on high-intensity statin therapy gained substantially more from icosapent ethyl

than those on low-intensity therapy. In the smaller subgroup receiving both a

statin and ezetimibe, icosapent ethyl also suggested a protective effect (HR =

0.82; 95% CI, 0.57–1.16), although this was not significantly different from the

statin-only group. This may be due to the limited sample size and the fact that

93% of participants were already on at least moderate-intensity statin therapy[3].

Taken toghether, our findings suggest the importance of lowering LDL to

optimize the cardioprotective effects of omega-3. However, the potential for

enhanced benefits through concurrent management of triglycerides and LDL-

C requires further validation.

Plasma proteins associated with omega-3 levels

Circulating proteins are often used as biomarkers or targets for

pharmacological intervention[45]. We incorporated pQTL data from the Fenland

study (n = 10,708) to detect plasma proteins associated with omega-3 levels.

Using SMR analysis combined with the HEIDI test (**Methods**), we identified 9

candidate proteins that passed the Bonferroni-corrected threshold (P_{SMR} <

2.59E-05; 0.05/1,927). Of these, five were further replicated in the secondary

omega-3 GWAS data (**Figure 5**), including Glucokinase Regulator (GCKR),

Angiopoietin Like 3 (ANGPTL3), Proprotein Convertase Subtilisin/Kexin Type

9 (PCSK9), T Cell Immunoglobulin And Mucin Domain Containing 4 (TIMD4),

and ApoB (**Table S6**). Regional plots revealed that genetic variants linked to

the expression of these proteins well colocalized with signals for omega-3

levels (**Figure S7 - S8**), highlighting strong associations between these

circulating proteins and omega-3 metabolism.

Gene set enrichment analysis demonstrated that these proteins were highly

enriched in pathways related to lipid homeostasis (GO:0055088; FDR =

1.91E-04) and triglyceride metabolic process (GO:0006641; FDR = 2.04E-04).

Of these, ANGPTL3 (β_{SMR} = 0.197, P_{SMR} = 1.22E-27 and P_{HEIDI} = 0.898),

PCSK9 (β_{SMR} = 0.192, P_{smr} = 1.15E-21 and P_{HEIDI} = 0.119), and ApoB (β_{SMR} = 0.488, P_{smr} = 1.57E-10 and P_{HEIDI} = 0.153) demonstrated a positive correlation with omega-3 levels (**Figure 5**). Their upregulations have been found linked to increased LDL-C levels and a higher risk of cardiovascular events[54-56]. These genetic findings suggest a potential mechanism whereby higher omega-3 levels are positively associated with proteins known to increase LDL-C (PCSK9, ANGPTL3, ApoB), which could partly explain their potential link to increased cardiovascular risk. However, this hypothesis requires further mechanistic studies and clinical validation.

Notably, PCSK9 and ANGPTL3 are established targets for FDA-approved drugs. Evolocumab, a PCSK9 inhibitor, has been shown to reduce LDL-C levels by 59% compared to placebo at 48 weeks[57], while Evinacumab, an ANGPTL3 inhibitor, achieves a 49% reduction in LDL-C and approximately 50% reductions in triglyceride levels relative to placebo at 24 weeks in patients with familial hypercholesterolemia[58]. In light of the MVMR and mediation analyses, omega-3 supplementation could be a valuable complement to PCSK9-targeted and ANGPTL3-targeted therapies. These hypotheses warrant further investigation.

Discussion

Using large-scale genetic data, we showed that genetically elevated omega-3 levels were associated with increased cardiovascular risk, particularly CAD, myocardial infarction, and heart failure. These results were consistent across independent omega-3 GWAS datasets and different MR algorithms. Additional sensitivity analyses also supported the positive causal relationship between higher omega-3 levels and increased cardiovascular risk. Although prior studies, such as STRENGTH and REDUCE- IT, reported neutral or protective effects, our results don't violate their findings, as these studies were conducted in patients receiving LDL-lowering therapy. Our MVMR and mediation analyses showed that effective LDL control is essential for omega-3 to confer cardiovascular benefits, providing a plausible explanation for the differing results between the disease population and the general population.

Notably, a recent prospective cohort study showed that regular use of fish oil
supplements was linked to a higher risk of first-time heart disease in
individuals without prior cardiovascular conditions, but slowed disease
progression in those with existing cardiovascular disease[59]. The differences
may also reflect the role of LDL control in mediating the protective effect of
omega-3, as individuals without cardiovascular conditions often use omega-3
supplementation without concurrent LDL-lowering therapy. Emerging
evidence[60] also suggests that LDL-C may act as a mediating factor between
increased fatty acids biosynthesis and higher cardiovascular risk. Consistent
with these findings, further analyses from the STRENGTH[4] and REDUCE-IT[3]
trials indicate that the protective effect of omega-3 on CAD is more
pronounced with intensive LDL-C-lowering therapy. Together, these findings
highlight the need for optimal lipid management, particularly LDL-C, when
using omega-3 supplementation to achieve cardiovascular protection.

Analysis of metabolic traits revealed that elevated omega-3 levels were
significantly linked to increased LDL-C, ApoB, and total cholesterol levels.
Circulating proteins known to increase LDL-C, such as PCSK9, ANGPTL3,
ApoB, were also found positively associated with omega-3 levels. These
findings well explain the positive association observed between omega-3 and
cardiovascular risk. However, mechanistic studies are needed to clarify the
underlying pathways. Omega-3 also showed a triglyceride-lowering effect,
though this benefit appeared to be mainly driven by the *FADS* gene cluster.
Previous clinical trials, including ComparED, STRENGTH and REDUCE-IT,
also support these findings.

Additionally, PCSK9 and ANGPTL3 are established targets of approved lipid-
lowering drugs[61,62]. Their positive associations with omega-3 levels raise the
possibility that omega-3 supplementation may interact with these pathways.
Further clinical studies are needed to assess whether combining omega-3
with therapies targeting PCSK9 or ANGPTL3 could enhance cardiovascular
benefits.

We acknowledge that MR methods rely on strong assumptions[23,63]. The
selection of valid IVs is crucial for producing reliable results. We restricted the

analyses to GWAS with large sample size (n > 50,000) and applied Steiger
filtering to exclude potential pleiotropy. Multiple well-established MR methods
were also utilized in combination to further enhance the reliability of the
findings. Despite these, completely ruling out horizontal pleiotropy and
ensuring sufficient statistical power remain challenging. In addition, some MR
analyses were conducted based on a one-sample test, where both exposure
and outcomes were collected from the same source, such as the UK Biobank.
This approach can minimize differences in population ancestry and
composition, but it is more susceptible to overfitting and weak instrument
bias[64].

In summary, this study suggests that the cardiovascular benefits of omega-3
fatty acids may depend on effective lipid management, particularly LDL-C
control. We hypothesize that combining omega-3 supplementation with
effective lipid-lowering therapy may help maximize cardiovascular benefit, a
concept that warrants further clinical investigation.

Conclusion

493 Our results suggest that the cardiovascular benefits of omega-3 fatty acids
494 are context-dependent, showing protective effects when lipids, particularly
495 LDL-C, are well controlled. We hypothesize that combining omega-3
496 supplementation with effective lipid-lowering therapy may help optimize
497 cardiovascular benefit, a concept that warrants further clinical investigation.

List of abbreviations

CAD：Coronary artery disease

MVMR：Multivariable Mendelian randomization

SMR：Summary-data-based Mendelian randomization

PUFAs：Polyunsaturated fatty acids

RCTs：Randomized clinical trials

MR：Mendelian randomization

IVs：Instrumental variables

GWAS：Genome-wide association studies

IVW：Inverse variance weighted

LDL-C：Low-density lipoprotein cholesterol

HDL-C：High-density lipoprotein cholesterol

ApoB：Apolipoprotein B

ApoA：Apolipoprotein A

BMI：Body mass index

T2D：Type 2 diabetes

T1D：Type 1 diabetes

LD：Linkage disequilibrium

SE：Standard errors

HEIDI：Heterogeneity in dependent instruments test

pQTL：Protein quantitative trait loci

Acknowledgments

We gratefully acknowledge funding supports from the Shenzhen-Hong Kong
Jointly Funded Project (Category A; SGDX20230116093201002) and the
Stability Support for Higher Education from Shenzhen Science and
Technology Program, the Guangdong Natural Science Foundation Youth
Enhancement Project (2024A1515030287), 1+1+1 CUHK-CUHK(SZ)-GDSTC
Joint Collaboration Fund (GRDP2025-056 and YSP05) and the National
Natural Science Foundation of China (82471825). We also extend our thanks
to the faculty development grant (Project number: H800005) from the Hang
Seng University of Hong Kong and the Warshel Institute for Computational
Biology and their funding support from Shenzhen City and Longgang District
(LGKCSDPT2024001). The authors thank the anonymous reviewers for their

constructive comments and valuable suggestions that helped to improve the quality of the manuscript.

Author contributions

Y.-F. Wang conceived the study. J.-H. Yu and C.-J. Li took the lead in data analysis. J.-H. Yu, C.-J. Z. Liu, Li, Y.-D. Chen, Y. Lei, D.-Y. Li, W. Ma, Y. Wang, Y. Yang, and R. Wang collected GWAS summary data. J.-H. Yu, C.-J. Li, Y. Wang, Y. Yang, R. Wang, and Y.-F. Wang contributed to the interpretation of the findings. J.-H. Yu, C.-J. Li and Y.-F. Wang wrote the manuscript. All authors read and contributed to the manuscript.

Competing interests

The authors declare no competing interests.

Role of study sponsors

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data availability

See **Table S1**.

Declaration of generative AI

We cautiously used ChatGPT 4.1 for linguistic and grammatical refinement to improve the readability during the proofreading. After using this tool, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.

References

1. Jayedi A, Shab-Bidar S. Fish Consumption and the Risk of Chronic Disease: An Umbrella Review of Meta-Analyses of Prospective Cohort Studies. *Adv Nutr*. Sep 1 2020;11(5):1123-1133. doi:10.1093/advances/nmaa029

2. Del Gobbo LC, Imamura F, Aslibekyan S, et al. omega-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort Studies. *JAMA Intern Med*. Aug 1 2016;176(8):1155-66. doi:10.1001/jamainternmed.2016.2925

3. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *The New England journal of medicine*. Jan 3 2019;380(1):11-22. doi:10.1056/NEJMoa1812792

4. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. *JAMA*. 2020;324(22):2268-2280. doi:10.1001/jama.2020.22258

5. Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. *Cold Spring Harb Perspect Med*. Jan 4 2022;12(1)doi:10.1101/cshperspect.a040501

6. Bowden J, M FDG, Minelli C, Smith GD, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I^2 statistic. *International Journal of Epidemiology*. 2016/12;45(6)doi:10.1093/ije/dyw220

7. Graham SE, Clarke SL, Wu KH, et al. The power of genetic diversity in genome-wide association studies of lipids. *Nature*. Dec 2021;600(7890):675-679. doi:10.1038/s41586-021-04064-3

8.   Koskeridis F, Evangelou E, Said S, et al. Pleiotropic genetic architecture and

novel loci for C-reactive protein levels. *Nat Commun*. Nov 14 2022;13(1):6939.

doi:10.1038/s41467-022-34688-6

9.   Karjalainen MK, Karthikeyan S, Oliver-Williams C, et al. Genome-wide

characterization of circulating metabolic biomarkers. *Nature*. Apr

2024;628(8006):130-138. doi:10.1038/s41586-024-07148-y

10.   Sinnott-Armstrong N, Tanigawa Y, Amar D, et al. Genetics of 35 blood and

urine biomarkers in the UK Biobank. *Nat Genet*. Feb 2021;53(2):185-194.

doi:10.1038/s41588-020-00757-z

11.   Guindo-Martinez M, Amela R, Bonas-Guarch S, et al. The impact of non-

additive genetic associations on age-related complex diseases. *Nat Commun*. Apr 23

2021;12(1):2436. doi:10.1038/s41467-021-21952-4

12.   Aragam KG, Jiang T, Goel A, et al. Discovery and systematic characterization

of risk variants and genes for coronary artery disease in over a million participants.

Nat Genet. Dec 2022;54(12):1803-1815. doi:10.1038/s41588-022-01233-6

13.   Hartiala JA, Han Y, Jia Q, et al. Genome-wide analysis identifies novel

susceptibility loci for myocardial infarction. *Eur Heart J*. Mar 1 2021;42(9):919-933.

doi:10.1093/eurheartj/ehaa1040

14.   van der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides

an Expanded View on the Genetic Architecture of Coronary Artery Disease. *Circ Res*.

Feb 2 2018;122(3):433-443. doi:10.1161/CIRCRESAHA.117.312086

15.   Shah S, Henry A, Roselli C, et al. Genome-wide association and Mendelian

randomisation analysis provide insights into the pathogenesis of heart failure. *Nat*

Commun. Jan 9 2020;11(1):163. doi:10.1038/s41467-019-13690-5

16.   Roselli C, Chaffin MD, Weng LC, et al. Multi-ethnic genome-wide

association study for atrial fibrillation. *Nat Genet*. Jun 11 2018;50(9):1225-1233.

doi:10.1038/s41588-018-0133-9

17.   Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association

study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.

Nat Genet. Apr 2018;50(4):524-537. doi:10.1038/s41588-018-0058-3

18.   Xue A, Wu Y, Zhu Z, et al. Genome-wide association analyses identify 143

risk variants and putative regulatory mechanisms for type 2 diabetes. *Nat Commun*.

Jul 27 2018;9(1):2941. doi:10.1038/s41467-018-04951-w

19.   Boehm FJ, Zhou X. Statistical methods for Mendelian randomization in

genome-wide association studies: A review. *Comput Struct Biotechnol J*.

2022;20:2338-2351. doi:10.1016/j.csbj.2022.05.015

20.   Hu X, Cai M, Xiao J, et al. Benchmarking Mendelian randomization methods

for causal inference using genome-wide association study summary statistics. *Am J*

Hum Genet. Aug 8 2024;111(8):1717-1735. doi:10.1016/j.ajhg.2024.06.016

21.   Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid

instruments: effect estimation and bias detection through Egger regression. *Int J*

Epidemiol. Apr 2015;44(2):512-25. doi:10.1093/ije/dyv080

22.   Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data

Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol*.

Dec 1 2017;46(6):1985-1998. doi:10.1093/ije/dyx102

23.   Hu X, Zhao J, Lin Z, et al. Mendelian randomization for causal inference

accounting for pleiotropy and sample structure using genome-wide summary statistics.

Proc Natl Acad Sci U S A. Jul 12 2022;119(28):e2106858119.

doi:10.1073/pnas.2106858119

24.   Slob EAW, Burgess S. A comparison of robust Mendelian randomization

methods using summary data. *Genet Epidemiol*. Jun 2020;44(4):313-329.

doi:10.1002/gepi.22295

25.   Richardson TG, Leyden GM, Wang Q, et al. Characterising metabolomic

signatures of lipid-modifying therapies through drug target mendelian randomisation.

PLoS Biol. Feb 2022;20(2):e3001547. doi:10.1371/journal.pbio.3001547

26.   Cerezo M, Sollis E, Ji Y, et al. The NHGRI-EBI GWAS Catalog: standards

for reusability, sustainability and diversity. *Nucleic Acids Res*. Jan 6

2025;53(D1):D998-D1005. doi:10.1093/nar/gkae1070

27.   Crouch DJM, Inshaw JRJ, Robertson CC, et al. Bayesian Effect Size Ranking

to Prioritise Genetic Risk Variants in Common Diseases for Follow-Up Studies.

Genet Epidemiol. Jan 2025;49(1):e22608. doi:10.1002/gepi.22608

28.   The Strengthening the Reporting of Observational Studies in Epidemiology

(STROBE) Statement: Guidelines for Reporting Observational Studies. *Annals of*

Internal Medicine. 2007;147(8):573-577. doi:10.7326/0003-4819-147-8-200710160-

00010 %m 17938396

29.   Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the

reporting of observational studies in epidemiology using mendelian randomisation

(STROBE-MR): explanation and elaboration. *BMJ*. Oct 26 2021;375:n2233.

doi:10.1136/bmj.n2233

30.   Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the

Reporting of Observational Studies in Epidemiology Using Mendelian Randomization:

The STROBE-MR Statement. *JAMA*. 2021;326(16):1614-1621.

doi:10.1001/jama.2021.18236

31.   Hemani G, Tilling K, Smith GD. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLOS Genetics*. 2017;13(11)doi:10.1371/journal.pgen.1007081

32.   Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol*. Nov 2013;37(7):658-65. doi:10.1002/gepi.21758

33.   Cinelli C, LaPierre N, Hill BL, Sankararaman S, Eskin E. Robust Mendelian randomization in the presence of residual population stratification, batch effects and horizontal pleiotropy. *Nat Commun*. Mar 1 2022;13(1):1093. doi:10.1038/s41467-022-28553-9

34.   Guan W, Steffen BT, Lemaitre RN, et al. Genome-wide association study of plasma N6 polyunsaturated fatty acids within the cohorts for heart and aging research in genomic epidemiology consortium. *Circ Cardiovasc Genet*. Jun 2014;7(3):321-331. doi:10.1161/CIRCGENETICS.113.000208

35.   Wald A. The Fitting of Straight Lines if Both Variables are Subject to Error. *The Annals of Mathematical Statistics*. 1940;11(3):284-300, 17.

36.   Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife*. May 30 2018;7doi:10.7554/eLife.34408

37.   Bulik-Sullivan BK, Loh PR, Finucane HK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. Mar 2015;47(3):291-5. doi:10.1038/ng.3211

38.   Carter AR, Sanderson E, Hammerton G, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. *Eur J Epidemiol*. May 2021;36(5):465-478. doi:10.1007/s10654-021-00757-1

39.   Cheng C, Spiegelman D, Li F. Estimating the natural indirect effect and the

mediation proportion via the product method. *BMC Med Res Methodol*. Nov 20

2021;21(1):253. doi:10.1186/s12874-021-01425-4

40.   Cheng C, Spiegelman D, Li F. Is the Product Method More Efficient Than the

Difference Method for Assessing Mediation? *Am J Epidemiol*. Jan 6 2023;192(1):84-

92. doi:10.1093/aje/kwac144

41.   Sobel ME. Asymptotic Confidence Intervals for Indirect Effects in Structural

Equation Models. *Sociological Methodology* 1982;

42.   David P. MacKinnon CML, Jeanne M. Hoffman, Stephen G. West, and Virgil,

Sheets. A Comparison of Methods to Test Mediation and Other Intervening

Variable Effects. *Psychol Methods*. 2002;

43.   Guo Y, Xu T, Luo J, et al. SMR-Portal: an online platform for integrative

analysis of GWAS and xQTL data to identify complex trait genes. *Nat Methods*. Feb

2025;22(2):220-222. doi:10.1038/s41592-024-02561-7

44.   Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and

eQTL studies predicts complex trait gene targets. *Nat Genet*. May 2016;48(5):481-7.

doi:10.1038/ng.3538

45.   Pietzner M, Wheeler E, Carrasco-Zanini J, et al. Mapping the proteo-genomic

convergence of human diseases. *Science*. Nov 12 2021;374(6569):eabj1541.

doi:10.1126/science.abj1541

46.   Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list

enrichment analysis and candidate gene prioritization. *Nucleic acids research*. Jul

2009;37(Web Server issue):W305-11. doi:10.1093/nar/gkp427

47.   Liu B, Gloudemans MJ, Rao AS, Ingelsson E, Montgomery SB. Abundant

associations with gene expression complicate GWAS follow-up. *Nat Genet*. May

2019;51(5):768-769. doi:10.1038/s41588-019-0404-0

48.   Loukil I, Mutch DM, Plourde M. Genetic association between FADS and

ELOVL polymorphisms and the circulating levels of EPA/DHA in humans: a scoping

review. *Genes Nutr*. Jun 6 2024;19(1):11. doi:10.1186/s12263-024-00747-4

49.   Borges MC, Haycock PC, Zheng J, et al. Role of circulating polyunsaturated

fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization

and fatty acid genetic association data from over 114,000 UK Biobank participants.

BMC Med. Jun 13 2022;20(1):210. doi:10.1186/s12916-022-02399-w

50.   Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association.

Nutrition C. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular

disease. *Circulation*. Nov 19 2002;106(21):2747-57.

doi:10.1161/01.cir.0000038493.65177.94

51.   Allaire J, Couture P, Leclerc M, et al. A randomized, crossover, head-to-head

comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to

reduce inflammation markers in men and women: the Comparing EPA to DHA

(ComparED) Study. *Am J Clin Nutr*. Aug 2016;104(2):280-7.

doi:10.3945/ajcn.116.131896

52.   Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol

by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new

HMG-CoA reductase inhibitor. *Arterioscler Thromb Vasc Biol*. May 1995;15(5):678-

82. doi:10.1161/01.atv.15.5.678

53. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin

Therapy after Acute Coronary Syndromes. *N Engl J Med*. Jun 18 2015;372(25):2387-

97. doi:10.1056/NEJMoa1410489

54. Huijgen R, Sjouke B, Vis K, et al. Genetic variation inAPOB,PCSK9,

andANGPTL3in carriers of pathogenic autosomal dominant hypercholesterolemic

mutations with unexpected low LDL-Cl Levels. *Human Mutation*. 2012;33(2):448-

455. doi:10.1002/humu.21660

55. Luo F, Das A, Khetarpal SA, et al. ANGPTL3 inhibition, dyslipidemia, and

cardiovascular diseases. *Trends in Cardiovascular Medicine*. 2024;34(4):215-222.

doi:10.1016/j.tcm.2023.01.008

56. Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and Pharmacologic

Inactivation of ANGPTL3 and Cardiovascular Disease. *New England Journal of*

Medicine. 2017;377(3):211-221. doi:10.1056/NEJMoa1612790

57. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical

Outcomes in Patients with Cardiovascular Disease. *New England Journal of Medicine*.

2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664

58. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous

Familial Hypercholesterolemia. *New England Journal of Medicine*. 2020;383(8):711-

720. doi:10.1056/NEJMoa2004215

59. Chen G, Qian ZM, Zhang J, et al. Regular use of fish oil supplements and

course of cardiovascular diseases: prospective cohort study. *BMJ Med*.

2024;3(1):e000451. doi:10.1136/bmjmed-2022-000451

60. Borges MC, Haycock P, Zheng J, et al. The impact of fatty acids biosynthesis

on the risk of cardiovascular diseases in Europeans and East Asians: a Mendelian

randomization study. *Hum Mol Genet*. Nov 28 2022;31(23):4034-4054.

doi:10.1093/hmg/ddac153

61.   Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous

Familial Hypercholesterolemia. *N Engl J Med*. Aug 20 2020;383(8):711-720.

doi:10.1056/NEJMoa2004215

62.   Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical

Outcomes in Patients with Cardiovascular Disease. *N Engl J Med*. May 4

2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664

63.   Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA,

Thompson JR. Assessing the suitability of summary data for two-sample Mendelian

randomization analyses using MR-Egger regression: the role of the I^2 statistic. *Int J*

Epidemiol. Dec 1 2016;45(6):1961-1974. doi:10.1093/ije/dyw220

64.   Nguyen K, Mitchell BD. A Guide to Understanding Mendelian

Randomization Studies. *Arthritis Care Res (Hoboken)*. Nov 2024;76(11):1451-1460.

doi:10.1002/acr.25400

763
764

Figure legends

Figure 1 Flowchart of Study Design.

Figure 2 Effect of omega-3 on cardiovascular events (a) and related metabolic traits (b) estimated across five mendelian randomization (MR) methods. nIVs, number of instrumental variables (IVs) used in the analysis. SE, standard error of the effect estimate. The APSS algorithm employs considerably fewer instrumental variables because it restricts analysis to SNPs included in the HapMap 3 reference panel (See Methods).

Figure 3 Effects of omega-3 on cardiovascular events with or without inclusion of variants in the FADS gene cluster. (a) Primary omega-3 GWAS derived from a multi-cohort study was used as the exposure. (b) Secondary omega-3 GWAS derived from UK Biobank (2022) was used as the exposure. The *FADS* gene cluster was defined as a region in hg19; chr11:61,067,097–62,134,826. The Bonferroni-adjusted significance threshold was set to be 0.00625 (0.05/8).

Figure 4 Enhanced Lipid control is essential for omega-3's cardiovascular protection. a) The direct effect of omega-3 on coronary artery disease by subsequently adjusting for variants associated with LDL-C, triglycerides and both lipid traits. b) Mediation analysis of the effect of omega-3 fatty acids on CAD risk through LDL-C. Red solid line illustrates the total effect of genetically predicted omega-3 on CAD. Step 1 (yellow solid line) represents the effect of omega-3 on LDL-C, and Step 2 (yellow solid line) represents the effect of LDL-C on CAD. The green dashed line indicates the indirect effect mediated by LDL-C. Indirect effect estimates of omega-3 on CAD through LDL-C using 4 MR methods. Error bars represent 95% CIs calculated using the Delta method (red) and Monte Carlo method (green). Yellow triangles represent proportion of the indirect effect relative to the total effect across 4 MR methods. c) Subgroup analyses from the STRENGTH and REDUCE-IT trials showed that the protective effect of omega-3 appeared to be associated with the intensity of LDL-C lowering therapy.

795 **Figure 5 Colocalization of protein QTLs (pQTLs) with genetic loci**
796 **associated with omega-3 levels.** Red dots show the results derived from the
797 primary omega-3 GWAS, and green dots represent the results based on the
798 secondary omega-3 GWAS. SE stands for Standard error.
799

Figure 1 Flowchart of Study Design

a)

Disease outcomes	Methods	nIVs	Beta	SE	*P*-value	Beta (Confidence Interval)
CAD (2022) (181, 522 cases, 984, 168 controls)						
	IVW	131	0.065	0.010	1.83e−11	
	MR Egger	131	0.037	0.018	4.16e−02	
	Weighted mode	131	0.019	0.005	2.65e−04	
	APSS	83	0.141	0.023	6.64e−10	
	FADS (rs174564−A)	1	0.012	0.006	3.70e−02	
CAD (2017) (34, 541cases, 261, 984 controls)						
	IVW	124	0.123	0.018	2.18e−12	
	MR Egger	124	0.074	0.033	2.45e−02	
	Weighted mode	124	0.052	0.010	2.87e−07	
	APSS	82	0.244	0.038	1.61e−10	
	FADS (rs174564−A)	1	0.036	0.012	2.00e−03	
Myocardial Infarction (61, 505 cases, 577, 716 controls)						
	IVW	121	0.068	0.009	4.88e−13	
	MR Egger	121	0.045	0.018	1.12e−02	
	Weighted mode	121	0.036	0.006	1.03e−07	
	APSS	82	0.128	0.020	7.03e−11	
	FADS (rs174564−A)	1	0.022	0.008	4.20e−03	
Heart Failure (47, 309 cases, 930, 014 controls)						
	IVW	123	0.019	0.004	1.16e−05	
	MR Egger	123	0.027	0.008	1.65e−03	
	Weighted mode	123	0.017	0.006	4.90e−03	
	APSS	82	0.024	0.009	4.84e−03	
	FADS (rs174564−A)	1	0.015	0.006	2.10e−02	
Atrial Fibrillation (60, 620 cases, 970, 216 controls)						
	IVW	131	0.008	0.003	9.45e−03	
	MR Egger	131	0.014	0.006	2.19e−02	
	Weighted mode	131	0.010	0.005	4.12e−02	
	APSS	83	0.011	0.006	7.22e−02	
	FADS (rs174564−A)	1	0.011	0.006	6.50e−02	
Stroke (40, 585 cases, 406, 111 controls)						
	IVW	121	0.018	0.006	1.40e−03	
	MR Egger	121	0.019	0.011	8.48e−02	
	Weighted mode	121	0.018	0.009	3.78e−02	
	APSS	83	0.015	0.011	1.79e−01	
	FADS (rs174564−A)	1	0.020	0.009	3.60e−02	
Ischemic Stroke (4, 217 cases, 406, 111 controls)						
	IVW	121	0.019	0.006	7.51e−04	
	MR Egger	121	0.022	0.011	4.60e−02	
	Weighted mode	121	0.018	0.009	3.52e−02	
	APSS	83	0.020	0.012	8.44e−02	
	FADS (rs174564−A)	1	0.024	0.010	1.29e−02	
Type 2 Diabetes (62, 892 cases, 596, 424 controls)						
	IVW	57	−0.010	0.012	3.97e−01	
	MR Egger	57	−0.001	0.019	9.62e−01	
	Weighted mode	57	0.025	0.008	3.71e−03	
	APSS	65	−0.022	0.015	1.39e−01	
	FADS (rs174564−A)	1	0.031	0.008	2.00e−04	
Type 1 Diabetes (n = 181, 214 samples)						
	IVW	91	−0.012	0.011	2.97e−01	
	MR Egger	91	0.003	0.020	8.67e−01	
	Weighted mode	91	0.010	0.013	4.44e−01	
	APSS	75	−0.031	0.017	6.91e−02	
	FADS (rs174564−A)	1	0.026	0.015	8.00e−02	

−0.2   0   0.3

b)

Metabolic traits	Methods	nIVs	Beta	SE	*P*-value	Beta (Confidence Interval)
Total Cholesterol (n = 1, 320, 016)						
	IVW	102	0.321	0.027	7.37e−33	
	MR Egger	102	0.226	0.047	6.70e−06	
	Weighted mode	102	0.147	0.004	3.55e−56	
	APSS	60	0.458	0.057	1.55e−15	
	FADS (rs174564−A)	1	0.163	0.005	1.85e−194	
LDL−C (n = 1, 320, 016)						
	IVW	112	0.250	0.021	2.48e−33	
	MR Egger	112	0.195	0.038	1.17e−06	
	Weighted mode	112	0.148	0.005	1.59e−57	
	APSS	68	0.330	0.044	9.00e−14	
	FADS (rs174564−A)	1	0.168	0.006	3.11e−191	
HDL−C (n = 1, 654, 960)						
	IVW	111	0.051	0.029	7.92e−02	
	MR Egger	111	0.073	0.054	1.78e−01	
	Weighted mode	111	0.157	0.005	9.01e−59	
	APSS	67	−0.087	0.056	1.22e−01	
	FADS (rs174564−A)	1	0.170	0.005	2.99e−243	
Triglycerides (2021) (n = 1,320,016)						
	IVW	112	0.007	0.032	8.30e−01	
	MR Egger	112	−0.169	0.058	4.16e−03	
	Weighted mode	112	−0.182	0.006	8.69e−59	
	APSS	65	0.079	0.048	9.88e−02	
	FADS (rs174564−A)	1	−0.205	0.006	2.42e−288	
Triglycerides (2022) (n = 361,194)						
	IVW	94	0.001	0.033	9.69e−01	
	MR Egger	94	−0.196	0.056	6.80e−04	
	Weighted mode	94	−0.176	0.009	3.61e−33	
	APSS	69	0.009	0.052	8.64e−01	
	FADS (rs174564−A)	1	−0.203	0.010	1.03e−83	
ApoB (n = 136, 016)						
	IVW	90	0.271	0.032	2.09e−17	
	MR Egger	90	0.109	0.053	4.40e−02	
	Weighted mode	90	0.091	0.013	2.61e−10	
	APSS	51	0.284	0.060	2.01e−06	
	FADS (rs174564−A)	1	0.093	0.017	5.61e−08	
ApoA (n = 323, 833)						
	IVW	23	0.074	0.068	2.76e−01	
	MR Egger	23	−0.03	0.166	8.58e−01	
	Weighted mode	23	0.018	0.037	6.36e−01	
	APSS	50	−0.101	0.066	1.27e−01	
	FADS (rs174550−T)	1	0.169	0.011	1.23e−52	
Hypertension (28, 391 cases, 28, 246 controls)						
	IVW	121	0.008	0.014	5.53e−01	
	MR Egger	121	−0.033	0.026	2.03e−01	
	Weighted mode	121	−0.028	0.023	2.15e−01	
	APSS	81	0.033	0.024	1.61e−01	
	FADS (rs174564−A)	1	−0.028	0.026	2.88e−01	

−0.5   0   0.6

Figure 2 Effect of omega-3 on cardiovascular events (a) and related metabolic traits (b) estimated across five mendelian randomization (MR) methods. nIVs, number of instrumental variables (IVs) used in the analysis. SE, standard error of the effect estimate. The APSS algorithm employs considerably fewer instrumental variables because it restricts analysis to SNPs included in the HapMap 3 reference panel (See Methods).

Figure 3 Effects of omega-3 on cardiovascular events with or without inclusion of variants in the *FADS* gene cluster. (a) Primary omega-3 GWAS derived from a multi-cohort study was used as the exposure. (b) Secondary omega-3 GWAS derived from UK Biobank (2022) was used as the exposure. The *FADS* gene cluster was defined as a region in hg19: chr11:61,067,097–62,134,826. The Bonferroni-adjusted significance threshold was set to be 0.00625 (0.05/8)

a)

Exposure	Outcome	Beta	SE	P-Value	Beta Coefficient (95% CI)
Non-adjusted					
Primary omega-3 (2024)	CAD (2022)	0.065	0.010	1.83e-11	
Primary omega-3 (2024)	CAD (2017)	0.123	0.018	2.18e-12	
Secondary omega-3 (2022)	CAD (2022)	0.031	0.008	1.21e-04	
Secondary omega-3 (2022)	CAD (2017)	0.066	0.012	1.26e-07	
Combined		**0.055**	**0.005**	**0**	
LDL-C-adjusted					
Primary omega-3 (2024)	CAD (2022)	-0.049	0.023	3.78e-02	
Primary omega-3 (2024)	CAD (2017)	-0.018	0.025	4.67e-01	
Secondary omega-3 (2022)	CAD (2022)	-0.026	0.020	1.91e-01	
Secondary omega-3 (2022)	CAD (2017)	-0.010	0.021	6.18e-01	
Combined		**-0.025**	**0.011**	**2.25e-02**	
Triglycerides-adjusted					
Primary omega-3 (2024)	CAD (2022)	0.165	0.021	8.56e-15	
Primary omega-3 (2024)	CAD (2017)	0.179	0.022	3.98e-16	
Secondary omega-3 (2022)	CAD (2022)	0.060	0.019	1.51e-03	
Secondary omega-3 (2022)	CAD (2017)	0.081	0.021	8.63e-05	
Combined		**0.116**	**0.010**	**0**	
LDL-C and Triglycerides-adjusted					
Primary omega-3 (2024)	CAD (2022)	-0.072	0.021	4.85e-04	
Primary omega-3 (2024)	CAD (2017)	-0.052	0.022	1.68e-02	
Secondary omega-3 (2022)	CAD (2022)	-0.073	0.018	4.10e-05	
Secondary omega-3 (2022)	CAD (2017)	-0.065	0.019	5.89e-04	
Combined		**-0.066**	**0.010**	**1.28e-11**	

b)

c)

Clinical trial	Placebo	Subgroup	Hazard ratio (95% CI)
STRENGTH, 2020	Corn oil	Baseline statin intensity	
Omega-3 CA		High	0.94 (0.81−1.08)
		Other	1.04 (0.91−1.20)
		Ezetimibe use	
		Yes	0.54 (0.34−0.86)
		No	1.02 (0.92−1.13)
REDUCE−IT, 2019	Mineral oil	Baseline statin intensity	
Icosapent Ethyl		High	0.69 (0.58−0.82)
		Moderate	0.76 (0.67−0.86)
		Low	1.12 (0.74−1.69)
		Ezetimibe use	
		Yes	0.82 (0.57−1.16)
		No	0.75 (0.67−0.83)

$P = 0.0094$ (STRENGTH Ezetimibe use)

$P = 0.034$ (REDUCE-IT Baseline statin intensity)

Figure 4 Enhanced Lipid control is essential for omega-3's cardiovascular protection. a) The direct effect of omega-3 on coronary artery disease by subsequently adjusting for variants associated with LDL-C, triglycerides and both lipid traits. b) Mediation analysis of the effect of omega-3 fatty acids on CAD risk through LDL-C. Red solid line illustrates the total effect of genetically predicted omega-3 on CAD. Step 1 (yellow solid line) represents the effect of omega-3 on LDL-C, and Step 2 (yellow solid line) represents the effect of LDL-C on CAD. The green dashed line indicates the indirect effect mediated by LDL-C. Indirect effect estimates of omega-3 on CAD through LDL-C using 4 MR methods. Error bars represent 95% CIs calculated using the Delta method (red) and Monte Carlo method (green). Yellow triangles represent proportion of the indirect effect relative to the total effect across 4 MR methods. c) Subgroup analyses from the STRENGTH and REDUCE-IT trials showed that the protective effect of omega-3 appeared to be associated with the intensity of LDL-C lowering therapy.

Colocalization	β_{SMR}	SE_{SMR}	P_{SMR}	P_{HEIDI}	β_{SMR} (95% Confidence Interval)
GCKR					
Primary omega−3 (2024)	−0.224	0.016	6.56e−45	0.097	
Secondary omega−3 (2022)	−0.258	0.017	4.94e−55	0.055	
ANGPTL3					
Primary omega−3 (2024)	0.197	0.018	1.22e−27	0.898	
Secondary omega−3 (2022)	0.254	0.019	3.85e−40	0.998	
PCSK9					
Primary omega−3 (2024)	0.192	0.020	1.15e−21	0.119	
Secondary omega−3 (2022)	0.107	0.018	4.65e−09	0.750	
TIMD4					
Primary omega−3 (2024)	−0.153	0.021	6.41e−13	0.030	
Secondary omega−3 (2022)	−0.126	0.021	9.51e−10	0.503	
APOB					
Primary omega−3 (2024)	0.488	0.076	1.57e−10	0.153	
Secondary omega−3 (2022)	0.334	0.059	1.74e−08	0.599	

Figure 5 Colocalization of protein QTLs (pQTLs) with genetic loci associated with omega-3 levels. Red dots show the results derived from the primary omega-3 GWAS, and green dots represent the results based on the secondary omega-3 GWAS. SE stands for Standard error.